Against which human papillomavirus types shall we vaccinate and screen? the international perspective

@article{Muoz2004AgainstWH,
  title={Against which human papillomavirus types shall we vaccinate and screen? the international perspective},
  author={N. Mu{\~n}oz and F. Bosch and X. Castellsagué and M. Diaz and S. de Sanjos{\'e} and D. Hammouda and Keerti V. Shah and C. Meijer},
  journal={International Journal of Cancer},
  year={2004},
  volume={111}
}
At least 15 types of HPV have been associated with cervical cancer, but current HPV vaccines confer only type‐specific immunity. To determine geographic variations in the HPV type distribution in cervical cancer, we carried out a pooled analysis of data from an international survey of HPV types in cervical cancer and from a multicenter case‐control study, both co‐coordinated by the IARC. Study cases were 3,607 women with incident, histologically confirmed cervical cancer recruited in 25… Expand
Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study.
TLDR
The currently available HPV prophylactic vaccines targeting types 16 and 18 have the potential to reduce the burden of cervical cancer in India by over 75%. Expand
Type-Specific Human Papillomavirus Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact.
TLDR
These results strongly indicate that prophylactic HPV vaccines can have a major impact in preventing CC in Tunisia. Expand
Human papillomavirus and HPV vaccines: a review.
TLDR
In women who have no evidence of past or current infection with the HPV genotypes in the vaccine, both vaccines show > 90% protection against persistent HPV infection for up to 5 years after vaccination, which is the longest reported follow-up so far. Expand
A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.
TLDR
It is estimated that HPV-16/18 vaccines will provide over 75% protection against ICC in South Asia and the addition of these additional HPV types in a second-generation vaccine could provide optimal cervical cancer prevention in this region. Expand
Human papillomavirus genotype in cervical cancer: A population‐based study
TLDR
Investigation of the human papillomavirus genotype distribution and correlation between HPV parameters and clinicopathological variables in cervical carcinoma treated in a large tertiary referral medical center in Taiwan found multiple‐type HPV sequences were more frequently seen in those receiving primary RT/CCRT. Expand
Human Papillomavirus type distribution in invasive cervical cancer in Uganda
TLDR
The results suggest that the currently available HPV vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in Uganda. Expand
Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination
TLDR
The findings suggest that natural HPV type competition does not exist, and that type replacement is unlikely to occur in vaccinated populations. Expand
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
TLDR
A meta‐analysis of HPV type‐specific prevalence data published from 1990 to 2010 found that overall HPV prevalence increased significantly and the proportion of ICC associated with HPV16 and/or 18 (HPV16/18) was between 70 and 76% in all world regions except Asia. Expand
Human papillomavirus type distribution in women from Asia: a meta‐analysis
  • Y. Bao, N. Li, J. Smith, Y. Qiao
  • Medicine
  • International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2008
TLDR
HPV type distribution in women with and without cervical neoplasia from Asia is determined and the potential future impact of an HPV 16/18 prophylactic vaccine in this region is estimated to be about 67% protection against ICC. Expand
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007
TLDR
The observed stability on the HPV type distribution predicts a high and stable impact of HPV vaccination in reducing the cervical cancer burden in future vaccinated generations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
TLDR
The results confirm the role of genitalHPVs, which are transmitted sexually, as the central etiologic factor in cervical cancer worldwide and suggest that most genital HPVs are associated with cancer, at least occasionally. Expand
Human papillomavirus infection and invasive cervical cancer in Paraguay
TLDR
Results of a further IARC case‐control study conducted in Asunción, Paraguay, to examine the association between specific HPV types and invasive cervical cancer as well as risk factors other than HPV found strong associations were found. Expand
Epidemiologic classification of human papillomavirus types associated with cervical cancer.
TLDR
In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82Should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic. Expand
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
TLDR
The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening. Expand
Prevalence of human papillomavirus in cervical cancer: A multicenter study in China
TLDR
HPV‐16 remained the most common HPV infection in both squamous cell carcinoma (SCC) and adenocarcinoma (AC), and the proportion of HPV‐18 infection was significantly higher in AC than in SCC. Expand
Human papillomavirus and invasive cervical cancer in Brazil.
TLDR
Number of sexual partners, early age at first intercourse, parity and duration of oral contraceptive use were significantly associated with an increased risk of cervical cancer and the very high risks found in this study further implicate this virus in the aetiology of cervicalcancer. Expand
The causal link between human papillomavirus and invasive cervical cancer: A population‐based case‐control study in colombia and spain
TLDR
There is a very strong association between HPV 16, 18, 31, 33 and 35 and invasive cervical cancer and that this association is probably causal. Expand
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
TLDR
A majority of ICC was associated with HPV16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region. Expand
A controlled trial of a human papillomavirus type 16 vaccine.
TLDR
Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer. Expand
Risk factors for cervical cancer in Thailand: a case-control study.
TLDR
New preventive strategies for cervical cancer will require the consideration of multiple HPV types, as well as limited education, increasing number of sexual partners, history of venereal diseases, and interval since last Pap smear test. Expand
...
1
2
3
4
...